hypophosphatemic rickets (저인산 혈성 구루병, 저인산염 혈성 구루병
| growth cone collapse | <cell biology> Loss of motile activity and cessation of advance by growth cones. There are now thought to be specific molecules that inhibit the motility of particular growth cones and are important in establishing correct pathways in developing nervous systems. See: axon pathfinding. (18 Nov 1997) |
|---|---|
| growth control | <cell biology> When applied to cells usually means control of growth of the population, i.e. Of the rate of division rather than of the size of an individual cell. (18 Nov 1997) |
| growth curve | A graphic representation of the change in size of an individual or a population over a period of time. (05 Mar 2000) |
| growth disorders | Deviations from the average values for a specific age and sex in any or all of the following: height, weight, skeletal proportions, osseous development, or maturation of features. The concept includes both acceleration and retardation of growth. (12 Dec 1998) |
| growth factors | Proteins involved in cell differentiation and growth.Growth factors are essential to the normal cell cycle, and are thus vital elements in the life of animals from conception to death. Among other things, they mediate foetal development, play a role in maintenance and repair of tissues, stimulate production of blood cells, and, gone awry, participate in cancerous processes. (05 Mar 2000) |
| growth hormone | <endocrinology, hormone> Polypeptide (191 amino acids) produced by anterior pituitary that stimulates liver to produce somatomedins 1 & 2. (13 Nov 1997) |
| growth hormone inhibiting hormone | <protein> Gastrointestinal and hypothalmic peptide hormone (two forms: 14 and 28 residues), found in gastric mucosa, pancreatic islets, nerves of the gastrointestinal tract, in posterior pituitary and in the central nervous system. Inhibits gastric secretion and motility: in hypothalamus/pituitary inhibits somatotropin release. (18 Nov 1997) |
| growth hormone-producing adenoma | <tumour> An adenoma that produces the clinical picture of gigantism or acromegaly, although a third of the cells have no granules or are a mixture of acidophils and chromophobes; some tumours may secrete both growth hormone and prolactin; often an acidophil or eosinophil adenoma. (05 Mar 2000) |
| growth hormone-regulating hormone | <endocrinology> Hypothalamic hormones that induce (somatoliberin) or inhibit (somatostatin) the release of growth hormone (somatotropin). (18 Nov 1997) |
| growth hormone-releasing hormone | <endocrinology> Peptide hormone related to the glucagon family, released from the pituitary, acts on the adenohypophysis to release growth hormone. Synonym: somatoliberin, growth hormone-releasing factor. (20 Sep 2002) |
| growth hormone stimulation test | <investigation> A test which measures the level of human growth hormone in response to the administration of the amino acid arginine. This test measures the ability of the pituitary gland to secrete growth hormone. Normal values in children are: 48 ng/ml. Normal values in men are 10 ng/ml. Normal values in women are 15 ng/ml. This test is used to evaluate infants with growth retardation. It may also be part of an evaluation for a pituitary tumour. Failure of arginine to raise growth hormone levels may indicate hypopituitarism or dwarfism. (27 Sep 1997) |
| growth hormone suppression test | <investigation> A test to determine if growth hormone is suppressed by hyperglycaemia. Growth hormone blood levels are determined sequentially after ingestion of a glucose-rich meal. If growth hormone levels remain elevated (after the glucose is given) then acromegaly or gigantism is suspected. (27 Sep 1997) |
| growth inhibitors | Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth (= plant growth regulators). (12 Dec 1998) |
| growth medium | <cell culture> A synthetic medium which is filled with nutrients necessary to the growth of microorganisms or cells being cultured in the lab. (09 Oct 1997) |
| growth milestones | <paediatrics> (1-3 years) In ascending order: masters walking, recognises gender differences, uses up to 8 words and understands simple commands, able to run, pivot and walk backwards, uses spoon to feed self, can name pictures of common objects, can point to body parts, imitates speech of others, begins pedaling tricycle, learns to take turns in play with other children, able to feed self neatly with minimal spill, able to say first and last name, able to draw a line when shown, dresses self with minimal help, learns to share toys without parent direction (12-18 years) In ascending order: boys exhibit secondary sexual characteristics (chest, facial, axillary and pubic hair growth voice changes, penile enlargement), movement into adult height/weight category, cognitive abilities move from simply concrete to abstract, peer acceptance and recognition is vital (3-6 years) In ascending order: rides tricycle well, able to draw a circle, able to draw stick figures, hops on one foot, catches a bounced ball, understands size concepts, enjoys rhymes and word play, able to skip, increased independence in performing tasks without parental assistance, begins to ride bicycle, understands time concepts, begins to recognise written words, starts reading skills, starts school (6-12 years) In ascending order: understands and is able to follow sequential directions, beginning skills for team sports, begins to lose baby teeth and erupt permanent teeth, reading skills develop further, peer recognition becomes important, girls begin to demonstrate secondary sexual characteristics (pubic hair, axillary hair, breast development), first menstrual period may occur (birth-1 year) In ascending order: displays social smile, rolls over by self, able to sit alone without support, babbling, plays peek-a-boo, eruption of first tooth, pulls self to standing position, walks while holding on to furniture or other support, says mama or dada in proper situations, able to drink from cup, understands NO and will stop activity in response, walks without support (27 Sep 1997) |